:Effect of aspirin and ticlopidine on PAF-induced platelet aggregation

概要

論文の詳細を見る
PAF-induced platelet aggregation and the effect of anti-platelet drugs (aspirin and ticlopidine) on PAF-induced platelet aggregation were investigated in various diseases and normal volunteers to reveal the role of PAF in human platelet aggregation.In various diseases, there was a close correlation between PAF-induced platelet aggregation and ADP-induced aggregation (Fig. 1). In a case of primary thrombocytemia, PAF-induced aggregation was remotely correlated with ADP-induced aggregation (Fig. 1).In thrombotic diseases, PAF-induced aggregation (the maximum aggregation rate), as well as ADP, was not remarkably affected by the aministration of aspirin (250-330mg/day), but was affected by ticlopidine (300-600mg/day). Collagen-induced aggregation which was inhibited by aspirin, was not remarkably affected by ticlopidine.In vivo, the administration of aspirin (1g) inhibited the second wave of PAF-induced aggregation and ATP secretion. But these inhibition was observed only in the restricted concentration of PAF.In vitro, aspirin did not inhibit PAF-induced aggregation and ATP secretion (Fig. 2).These results suggest that, in human platelet aggregation, PAF plays a role different from ADP and induces the aggregation mainly via the pathway different from the cyclooxygenase pathway.
一般社団法人日本血栓止血学会の論文